As a result of marketing efforts and customer commitments made in the 1st Quarter, our cancer test orders increased ten-fold in April, compared to average monthly test volume over the previous 12 months. We are currently optimistic that this demand may continue to increase quarter-over-quarter for the foreseeable future.   Marketing efforts to date combine direct-to-consumer and retail clinics.

Firefighters, of which there are over one million in the U.S. alone, represent an important segment of our current American customer base.  For example, over 500 tests are expected to be purchased during the 2nd Quarter from only four small suburban fire departments.  This trend results from the following:

On April 30 Maryland's Governor Hogan signed into law the nation's first grant program to fund innovative cancer screening tests for state fire departments. 20/20's CEO, himself a former volunteer firefighter, was the architect of SB 727. We expect that fire departments using OneTest will be well positioned to compete for these funds. A similar bill will likely be introduced in Delaware very soon.

The tumor markers measured in OneTest--CEA, CA-125, CA-15.3, CA-19.9, AFP, PSA, and Cyfra--are routinely used in thousands of clinical laboratories worldwide, although the particular markers offered and the testing equipment utilized often varies by region, lab, and clinic. The most common tumor markers used for screening are CEA, AFP, CA-125, and PSA and the most common diagnostic test manufacturers are Roche Diagnostics, Abbott Diagnostics, Siemens Healthcare, and Beckman-Coulter.

To make our technology available for the widest possible global market, in Q1 we conducted extensive side-by-side studies comparing biomarker detection kit performance of each of these four manufacturers and integrated the results into our software . Moreover we created a truncated version of our machine learning algorithm to accommodate clinics that only offer the four most common biomarker tests.